A previous meta-analysis of cancers demonstrated that a high TIGIT expression is correlated with worse OS and PFS [19], and in hematological malignancies, high TIGIT expression is associated with poor clinical outcomes in patients with follicular lymphoma [20] and AML [21,22]. This evidence concerns the gene TIGIT and hematologic disorder.